Table 4.

Guideline concordant primary treatment and race/ethnicity by breast cancer subtypes

Non-Hispanic whiteAfrican AmericanHispanic whiteAsian/Pacific IslanderAmerican Indian/Alaska Native
n = 26,980n = 3,380n = 3,428n = 3,066n = 199
n (%)n (%)OR (95% CI)n (%)OR (95% CI)n (%)OR (95% CI)n (%)OR (95% CI)
All subtypesa
 Concordant23,538 (87.2)2,774 (82.1)Ref2,882 (84.1)Ref2,691 (87.8)Ref168 (84.4)Ref
 Nonconcordant3,442 (12.8)606 (17.9)1.4 (1.3–1.6)546 (15.9)1.3 (1.2–1.4)375 (12.2)1.0 (0.9–1.1)31 (15.6)1.3 (0.9–1.9)
HR+/HER2b
 Concordant18,994 (88.1)1,926 (84.4)Ref2,220 (85.4)Ref2,104 (88.5)Ref140 (84.3)Ref
 Nonconcordant2,577 (11.9)357 (15.6)1.3 (1.2–1.5)380 (14.6)1.3 (1.1–1.4)275 (11.5)1.0 (0.8–1.1)26 (15.7)1.3 (0.9–2.1)
Triple negativeb
 Concordant1,862 (83.2)447 (75.1)Ref282 (80.6)Ref174 (86.6)Ref7 (77.8)Ref
 Nonconcordant376 (16.8)148 (24.9)1.6 (1.3–2.0)68 (19.4)1.2 (0.9–1.6)27 (13.4)0.8 (0.5–1.2)2 (22.2)1.5 (0.3–7.1)
HR+/HER2+b
 Concordant1,951 (84.3)277 (79.6)Ref269 (79.1)Ref268 (83.0)Ref14 (82.4)Ref
 Nonconcordant363 (15.7)71 (20.4)1.4 (1.0–1.8)71 (20.9)1.4 (1.1–1.9)55 (17.0)1.1 (0.8–1.5)3 (17.6)1.2 (0.3–4.1)
HR/HER2+b
 Concordant731 (85.3)124 (80.5)Ref111 (80.4)Ref145 (89.0)Ref7 (100.0)NA
 Nonconcordant126 (14.7)30 (19.5)1.4 (0.9–2.2)27 (19.6)1.5 (0.9–2.4)18 (11.0)0.7 (0.4–1.2)0 (0.0)
  • aORs adjusted for age groups, stage (I vs. II), and breast cancer subtypes.

  • bORs adjusted for age and stage (I vs. II). ORs are in bold if P values are <0.05.